Aim: We investigated if imaging and pathology features could help to identify a high axillary tumor burden (ATB) in breast cancer patients, in order to individualize decisions on axillary lymph node (ALN) dissection (ALND). Methods: We retrospectively analyzed patients primarily treated with surgery in our unit between 2011 and 2014. We divided the patients in two groups: low ATB (LATB) if ≤ 2 ALN were infiltrated and high ATB (HATB) if > 2 ALN were infiltrated. Results: Data of 105 patients was included in the study. Axillary ultrasound (AUS) features associated with HATB were any sign of ALN infiltration (76 vs 24%, P = 0.027) and > 2 suspicious ALNs (73% vs 27%, P = 0.018); however, when AUS revealed ≤ 2 suspicious ALNs, 39% of these patients had HATB. Any sign of ALN infiltration on magnetic resonance imaging was associated with HATB (48% vs 52%, P = 0.031). Positive preoperative ALN cytology or biopsy was associated with HATB (53% vs 47%, P = 0.008), while p53 positivity (80% vs 20%) and high histological grade (68% vs. 32%) correlated with LATB (P = 0.05 and P = 0.02, respectively). In multivariate analysis, only positive preoperative ALN cytology or biopsy was associated with HATB (P = 0.038). Conclusions: AUS was useful for detecting HATB but was not as effective in patients with LATB. Proving axillary infiltration with AUS-directed cytology or biopsy is the most effective method to predict HATB.
Introduction
Axillary staging in breast cancer is essential to assess prognosis and plan treatment, but its management remains controversial. When the ACOSOG Z0011 and AMAROS trials were conducted, several breast units stopped performing axillary lymph node dissection (ALND) in patients with one or two affected sentinel lymph nodes (SLN) as these studies proved that ALND was not superior to direct or indirect axillary irradiation. 1, 2 Since these trials were conducted, several systematic reviews and meta-analyses have supported this data. 3, 4 On the other hand, a recent meta-analysis of randomized trials of ALND versus no ALND showed an improvement in overall survival (OS) and disease-free survival (DFS) in patients who underwent ALND. 5 Importantly, a randomized trial also reported that irradiation of lymph node areas improved DFS and distant DFS. 6 These studies suggest that treating the lymph node neoplastic burden with surgery or radiation in some patients could achieve the best results for breast cancer treatment.
As a consequence of these studies, patients with a low neoplastic axillary burden could safely be spared ALND, as systemic treatments and indirect or direct radiotherapy would be adequate to treat the regional spread of the disease. 7 Patients with a high axillary tumor burden (HATB), especially those not responding to systemic treatments, could be candidates for ALND.
The aim of our study was to evaluate if information obtained through preoperative axillary ultrasound (AUS) and magnetic resonance imaging (MRI) reports, together with pathological tumor features obtained from the diagnostic biopsy, could be useful to estimate the axillary tumor burden (ATB) in patients with an infiltrated axilla; if reliable enough they could be useful to decide the best therapeutic option.
Methods
We planned a retrospective cohort study. Female patients with a first diagnosis of invasive carcinoma treated at our Breast Functional Unit between July 2011 and December 2014 were identified from the Tumour Registry of Hospital del Mar, prospectively maintained by the Epidemiology Department. Patients with axillary lymph node (ALN) infiltration treated primarily with surgery, including ALND, were included in the study, if the pathology report quantified axillary neoplastic infiltration.
Patients who received systemic neoadjuvant treatment were excluded. In the Breast Cancer Unit of our institution, criteria have been established to recommend neoadjuvant treatment in patients with locally advanced operable carcinomas (some stages I, stages II-III) that could obtain a surgical conservative benefit, as well as for testing a pathological complete response that will improve prognosis and survival.
We constructed a new database using the Microsoft Access application including Tumour Registry data prospectively obtained and new data retrospectively obtained. The prospectively collected data included patient age, diagnostic biopsy date, diagnostic biopsy data, type of surgery performed, and histological and molecular data of the surgical specimen. The retrospectively collected data were obtained from clinical records, including imaging features and indications for ALND for each patient. Indications to perform an ALND during the study period included staging purposes -multicentric disease, T3 or T4 tumorpreoperative positive ALN cytology or biopsy (PPCB) and a positive SLN.
The Ethical Committee for Clinical Research of our research center, the Institut Mar d'Investigacions Mèdi-ques (IMIM), approved the study. The study followed the recommendations of the Helsinki Declaration.
Pathology processing
Our standardized institution protocol was followed to process breast surgery specimens. Briefly, all specimens were inked and sectioned at 3 mm intervals and then fixed in 10% neutral buffered formalin for a period ranging from 24 to 48 h. If possible, the entire specimen was submitted for paraffin processing. When not possible, the specimen was sampled using systematic mapping. Hematoxylin and eosin (H&E) slides were evaluated. If a carcinoma was present in only one section, its size was measured in this single slide. When multiple foci affecting multiple sections were found (i.e. multifocal disease), carcinoma size was estimated adding the measurements of each focus taking into account the diagram of the specimen, the location of the involved blocks and the thickness of the sample submitted in each block. If reexcision was necessary because of involved margins, pathologists used the newly excised biopsy cavity as a landmark for additional size estimation. In addition to lesion extent, the pathological type, histological grade and the presence/absence of comedonecrosis were systematically reported.
A routine technique was also developed for SLN and ALND histological examinations. SLN were examined by serial sectioning: they were cut into 2 mm slices and for each slice, six sections of 4 μm were obtained, leaving 20 μm of separation between them. Three alternate sections were stained with routine H&E and if negative, the remaining sections were immunohistochemically studied using cytokeratin. For ALND, 3 mm slices were obtained for each node and for each slice a single 4 μm section was stained with routine H&E.
Following our Pathology Department protocol, immunohistochemical analysis was systematically performed including estrogen receptor (ER), progesterone receptor (PR) and p53, Her2-Neu and Ki67 proliferation index expression. ER, PR and p53 were reported on a semi-quantitative scale describing the percentage of positive cells and staining intensity. Ki 67 was reported describing the percentage of positive cells. Her-2-Neu expression by immunohistochemistry was reported as negative (0,1+), borderline (2+) or positive (3+). Specimens with Her-2-Neu borderline immunohistochemical expression were processed through in situ hybridization (ISH) to rule out Her-2-Neu gene amplification.
Statistical analysis
We categorized patients into two groups depending on the number of lymph nodes found to be affected in the pathology specimen of the ALND: low ATB (LATB) if ≤ 2 nodes were affected and HATB if > 2. We chose this cut-off because it was the inclusion criteria used in the Z0011 trial.
1 Both groups were compared regarding age, tumor size, number of lymph nodes retrieved in the ALND and number of ALN infiltrated. The imaging features identified in imaging reports and evaluated as ATB predictors were: AUS reporting suspected ALN infiltration, number of lymph nodes suspected to be infiltrated in AUS, type of features suggesting infiltration in AUS (cortical thickening of 3 mm or more, lymph node structure loss and extracapsular neoplastic infiltration) and axillary infiltration suspected in MRI (cortical thickening of ≥ 3 mm, high activity, lymph node structure loss). The pathology features evaluated as ATB predictors were a PPCB, size of the main tumor (pT), breast cancer pathology subtypes (infiltrating ductal carcinoma, lobular infiltrating carcinoma or other), breast cancer immunophenotypes (luminal A, luminal B, Her2-enriched or triple negative), histological grade, number of neoplastic foci (unifocal, multifocal or multicentric neoplasia), ER expression and PR expression. Her2 positivity was shown by immunohistochemistry or by ISH, p53 expression, Ki67 expression and lymphovascular infiltration.
We performed statistical analysis using PAWS version 18.0. Continuous data were compared using Student's t and Mann-Whitney U tests. Categorical data were compared using Chi-squared and Fisher's exact tests. We used a receiver operating characteristic curve to determine tumor size, a continuous variable. Bilateral statistical significance was met if P ≤ 0.05.
Results
During the study period, 244 patients with infiltrated ALN were treated via ALND in our unit; 139 patients who received systemic neoadjuvant treatment were excluded, leaving 105 patients for the study. ALND was conducted in 15 patients for staging purposes, in 28 because of a positive SN and in 62 because of positive cytology in 56 and positive core biopsy in 6. Among these 105 patients, 60 were classified as the LATB group and 45 as the HATB group. Figure 1 summarizes the recruitment flow of the study.
The characteristics of each group regarding age, average tumor size, number of lymph nodes retrieved in the ALND and number of infiltrated lymph nodes are summarized in Table 1 . There were no significant differences in age, number of lymph nodes retrieved or tumor size between the two groups, although tumor size tended to be higher in the HATB group. As expected, the number of infiltrated lymph nodes was significantly higher in the HATB than in the LATB group. In bold text P < 0.05. ALN, axillary lymph nodes; ALND, axillary lymph node dissection; HATB, high axillary tumor burden; LATB, low axillary tumor burden.
Suspicious lymph nodes were detected by AUS in 76 of the 105 patients. The average number of suspicious nodes was 1.22 (standard deviation [SD] 1.21) in the LATB group and 2.17 (SD 1.72) in the HATB group; this difference was significant (Mann-Whitney U P = 0.003). Features of the suspicious nodes in 58 patients included: cortical thickening in 40 (38.1%), lymph node structure loss in 14 (13.3%) and extracapsular neoplastic extension in 4 (3.8%) (Fig. 2) . The results of bivariate analysis of the imaging features evaluated as predictors of axillary tumor load are summarized in Table 2 . Suspicion of ALN infiltration and suspicion of > 2 ALN being infiltrated was more frequent in the HATB group and the difference was significant. Of note, when the AUS report described ≤ 2 ALN infiltrated, 39% of these patients had HATB. Regarding the description of features suggesting infiltration in the AUS, there were no statistical differences in any of the three descriptions evaluated; lymph node structure loss tended to be more frequent in the HATB group. Regarding MRI, suspected ALN infiltration was more frequently reported in the HATB group and the difference was also significant ( Table 2) .
Bivariate analysis of the pathological features evaluated is summarized in Table 3 . There were significant differences in PPCB, P53 positivity and histological grade between the two groups. A PPCB occurred significantly more often in the HATB group. P53 was positive in 14.2% of the samples (n = 14) and was significantly associated with LATB. High tumor grade was also significantly associated with LATB. There were no significant differences in other pathological features between the two groups.
The only significant predictive factor of HATB in multivariate analysis was a PPCB (P = 0.038); p53 positivity was marginally significant (P = 0.068) as a predictor of LATB (Table 4) .
Discussion
The main objective in the current treatment of breast cancer is to achieve the best OS and DFS with minimal secondary effects. In this sense, the Z0011 trial and other research trials observed that it was possible to spare ALND in patients with no suspicious ALN after clinical exploration and only one or two positive SLNs were detected. 1, 8, 9 Preoperative AUS was not systematically used in patients included in the Z0011 trial; however, it is a technique now systematically used in many breast units, including ours. Our results suggest that AUS shows good efficacy for predicting HATB but could be suboptimal when predicting infiltration of only one or two ALN: in 39% of cases where AUS predicted a LATB, the final pathologic exam confirmed > 2 nodes with neoplastic disease. When axillary disease is low, radiological techniques have less precision to detect ALN infiltration, and features of suspicious nodes on AUS could be more easily disregarded. This has also been confirmed by previous studies. [10] [11] [12] As a consequence of results of the Z0011 trial, some authors have suggested that breast centers performing Lymph node structure loss Figure 2 Suspicious nodes observed on axillary ultrasound. In bold text P < 0.05. AUS, axillary ultrasound; HATB, High axillary tumor burden; LATB, low axillary tumor burden.
systematic AUS for preoperative breast cancer staging could be overtreating patients, as AUS may be able to detect a very low axillary neoplastic burden that physical exploration cannot detect. Patients with SN who may not need to undergo ALND according to Z0011 criteria, would undergo direct ALND in the centers performing preoperative AUS. 13 This conclusion is not supported by the results of our research or the results of other studies: a PPCB is a proven risk factor for a HATB. 14, 15 New ongoing trials may add information of the advantages and disadvantages of this approach, in order to clarify the utility of AUS (e.g. POSNOC -A Trial Looking At Axillary Treatment In Early Breast Cancer NCT02401685).
In our study, MRI results revealing suspected axillary neoplastic infiltration were significantly associated with HATB in bivariate analysis, but lost significance in multivariate analysis. The role of preoperative axillary MRI, if any, remains to be established in this setting. Our results should be interpreted with caution because of the lower number of cases for which MRI was performed compared to AUS. The combination of both techniques could not be calculated because of the small sample.
We evaluated pathological features to predict axillary tumor load, as it is well known that different breast cancer immunophenotypes show different metastatic patterns. 16, 17 We concluded that a p53 positivity burden together with a high histological grade were associated with a low axillary tumor load. This conclusion is consistent with the results of our previous study. 18 Positive p53 breast cancers, although aggressive, could explain low axillary involvement because they would mainly start hematological dissemination during tumor growth. 19 In the present study, significant differences were observed in bivariate analysis but not in multivariate analysis. New current studies at our institution with larger patient samples should clarify if these pathology features could be of any help when preoperatively evaluating the axillary tumor load.
Multivariate analysis included all of the imaging and pathological features evaluated and the only feature that kept its significance was the existence of a PPCB; this was associated with the HATB group. This result is consistent with the results of many other studies and supports the indication made by many international guidelines recommending ALND in this setting. 20 Our study has some limitations. First, it was a single institution analysis with a limited number of patients. Second, ALND was realized because of different indications, therefore the results regarding AUS should be analyzed independently. 21 Third, during the study period, the AUS report was not systematized and, as a consequence, the imaging features evaluated could not be retrieved for all of the patients evaluated; thus, information bias cannot be ruled out.
In conclusion, our study showed that, in our institution, AUS showed better efficacy for predicting HATB In bold text P < 0.05. ER, estrogen receptor; HATB, high axillary tumor burden; LATB, Low axillary tumor burden; PPCB, preoperative positive axillary lymph node cytology or biopsy; PR, progesterone receptor.
than LATB. p53 positivity and histological grade may be of some value to predict LATB. Consistent with the results of other studies, a PPCB was significantly associated with HATB. Future prospective studies are needed to determine if surgical decisions should be individualized depending on the pathological features and axillary evaluation through imaging. Meanwhile, it is reasonable to perform ALND when a PPCB is obtained as current evidence supports that the probability of HATB is high. In bold text P < 0.05. AUS, axillary ultrasound; MRI, magnetic resonance imaging; PPCB, preoperative positive axillary lymph node cytology or biopsy.
